Log in with your email address username.


[Correspondence] Optimum technique to reduce risk of stent thrombosis – Authors’ reply

We agree with Rahman Shah that although no significant differences in device thrombosis between the Absorb everolimus-eluting bioresorbable vascular scaffold (BVS) and the Xience metallic everolimus-eluting stent (EES) were present, our study1 with 3389 randomised patients was underpowered to detect small differences in this low-frequency endpoint, and that the suggestion of increased thrombosis with BVS might represent a type II error.